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Abstract
Coronary artery disease (CAD) is one of the major cardiovascular diseases and represents the leading causes of global mortality. Developing new diagnostic and therapeutic approaches for CAD treatment are critically needed, especially for an early
accurate CAD detection and further timely intervention. In this study, we successfully
isolated human plasma small extracellular vesicles (sEVs) from four stages of CAD
patients, that is, healthy control, stable plaque, non-ST-elevation myocardial infarction, and ST-elevation myocardial infarction. Surface-enhanced Raman scattering
(SERS) measurement in conjunction with five machine learning approaches, including
Quadratic Discriminant Analysis, Support Vector Machine (SVM), K-Nearest Neighbor, Artificial Neural network, were then applied for the classification and prediction
of the sEV samples. Among these five approaches, the overall accuracy of SVM
shows the best predication results on both early CAD detection (86.4%) and overall
prediction (92.3%). SVM also possesses the highest sensitivity (97.69%) and specificity (95.7%). Thus, our study demonstrates a promising strategy for noninvasive, safe,
and high accurate diagnosis for CAD early detection.

Xi Huang and Bo Liu contributed equally to this work.
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I N T RO DU CT I O N

sEVs are secreted by all cells in both normal and diseased tissues, and
can be further categorized based on their biogenesis, size, and bio-

Coronary artery disease (CAD) is represented by the accumulation of

physical properties, such as exosomes, apoptotic bodies, microvesi-

atheromatous plaques within the walls of the arteries that supply

cles, ectosomes, and other vesicles.20–23 sEVs are found in most

blood to the heart.1 CAD is one of the major cardiovascular diseases

biological fluids and contain a wide variety of cargo, such as proteins,

2–4

and remains the leading causes of death worldwide.
5,6

CAD is

lipids, nucleic acids and metabolites.21,24,25 These cargoes are repre-

Based on the

sentative of their cellular origin and reflective of the pathological con-

degree of stenosis and plaque characteristics, CAD patients can pre-

dition of the origin tissue and cells, which may serve as noninvasive

sent clinically with cardiac symptoms and can be divided into different

diagnostic biomarkers in biological fluids.26–28 Numerous studies have

categories, that is, patients with stable nonobstructive plaques (SP),

reported the value of exploiting sEV in diagnostic and therapeutic

non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation

applications in the central nervous,29,30 cancer,31,32 and visceral organ

myocardial infarction (STEMI). This reflects the continuum of CAD

diseases.33,34 The cargoes of these sEVs reflect the molecular content

and with increased severity there are decreased lumen areas, greater

and pathology of their original cells.23 Therefore, sEVs isolated from

plaque burden, more plaque rupture all of which are associated with a

liquid and tissue biopsies can serve as potential biomarkers to follow

greater risk of mortality.1,7 Thus, there is still a huge need to develop

disease progression.35–39 Different diseases are expected to alter

new diagnostic and therapeutic approaches for CAD treatment, espe-

either the sEV contents or the sorting and packaging process37,39 and

cially an early accurate CAD detection and timely intervention, which

these alterations are expected to be detectable and be useful in diag-

is expected to avert many late CAD events and deaths.

nosis for evaluating disease activity and/or the response to therapy.40

responsible for about 7 million deaths worldwide.

In the past few decades, various preventive and therapeutic strat-

Plasma as an important component of blood, has the characteristics of

egies have substantially improved the prognosis of patients suffering

representing systemic disease pathology.41 In the cardiovascular sys-

from CAD. Many advanced techniques have been developed,

tem, sEVs are associated with endothelial cells, cardiac myocytes, vas-

reported, and clinically applied to the diagnostic and prognostic

cular cells, progenitor and stem cells, and play an essential role in the

workup of CAD, such as electrocardiogram,8,9 echocardiography,10

development, injury and disease of the cardiovascular system.28,42

11,12

intravascular imaging,

13,14

coronary angiography.

Although these

diagnostic methods have revolutionized the management of CAD

Thus, cardiovascular-derived plasma sEVs have great potential as
potential diagnostic biomarkers for CAD screening.

patients, the prevalence of adverse cardiac events remains high. Imag-

Surface-enhanced Raman scattering (SERS) is a commonly used

ing approaches, like coronary angiography, are invasive and should

sensing technique in which inelastic light scattering by molecules is

not be used to diagnose the early-stage CAD. Some chemical agents

greatly enhanced when the molecules are absorbed onto corrugated

used in cardiac stress testing, such as radiocontrast media may have

metal surfaces (usually Au).43,44 The label-free, nondestructive and

potential side effects for CAD patients. As well, these stress tests are

noninvasive characteristics of SERS enable its biomedical application

designed to detect significant CAD which represents a luminal loss of

to the diagnosis of diseases, such as neurodegenerative disorders,45

more than 50%. Novel biomarkers can predict and differentiate

cancer,46,47 or diabetes.48 This innovative technique has also been

between CAD types in both the early and late stages, and may reduce

used to diagnose lung cancer by combing with exosomes by pattern

unnecessary invasive coronary angiography and thus enhance predic-

analysis of SERS data.49,50 Thus, SERS has the potential to differenti-

15

However, the detection sensitivity of these biomarkers

ate sEVs based on their different membrane lipid/protein contents

has been lower due to the use of large amounts of capturing and

along with other various functional groups. However, the Raman sig-

labeled detecting antibodies, which may increase the risk of false posi-

natures of sEVs are expected to be highly complex due to the overlap-

tivity due to nonspecific binding with nontarget analytes, especially

ping. The common solution is to analyze the entire Raman spectra as

for early CAD stage.16,17 In addition, patients may not have any symp-

“fingerprint” input by leveraging the power of machine learning (ML).

toms in the early CAD stage reflective of nonobstructive CAD stage

The sEVs collected from patients with different stages of CAD have

(SP stage). Therefore, the prompt, economical, and accurate low-risk

“impact” on the entire Raman spectra (spectral shapes), although the

diagnosis and prognosis for CAD in asymptomatic patients are crucial

changes are usually small and very difficult to be detected. By ML

to allow timely prevention and therapeutic treatments to improve

algorithms and large training data set, it is possible to detect common

patients' quality of life prior to the event. Enhancing the early diagno-

“patterns” from the hundreds of Raman spectra with training data and

sis of CAD and utilization of therapeutic approaches to prevent pro-

then the algorithm can perform prediction in blind tests. ML has been

gression is crucial for the management and prevention of CAD.

extensively applied in analyzing spectroscopic signals for complex bio-

tive value.

Small Extracellular vesicles (sEVs) are small lipid-bilayer enveloped

samples and has achieved satisfying results. Thus, by using ML

assemblies with sizes ranging from 20 nm to several micrometers.18,19

assisted analysis on a high-dimensional SERS database, valuable
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F I G U R E 1 Schematic illustration of ML-assisted sEV analysis for CAD diagnosis. (a) Isolation of sEVs from the human plasma of patients with
different CAD stages, including HC, SP, NSTEMI and STEMI stages, and collection of spectroscopic data of plasma-derived sEVs by SERS.
(b) Overview of ML-assisted plasma sEV classification and CAD diagnosis using sEVs SERS signal patterns. This illustration is created by
BioRender.com with an authorized license

information is expected to be extracted for accurate estimation and

(Figure 1a). Then, the SERS spectra of plasma-derived sEVs were

practical prediction of known CAD stages which when validated can

obtained by Raman microscopy and analyzed using five supervised

be used clinically as a diagnostic tool.

ML models (Figure 1b), including Quadratic Discriminant Analysis

In this study, we demonstrated a noninvasive, label-free SERS

(QDA), Support Vector Machine (SVM), K-Nearest Neighbor (KNN),

technique to diagnose CAD by assessing and monitor progression of

Artificial Neural network (ANN), and XGBoost (XGB). Then, 90% of

the disease. To the best of our knowledge, direct, label-free in vitro

SERS data set of sEVs were used to train the models. The supervised

characterization of sEVs for the early CAD stage diagnosis through

models classified the sEVs data into four clusters (one HC group and

SERS at a biomolecular level has not previously been demonstrated. A

three stages of CAD). The remaining 10% spectral data were used to

Raman spectral library of plasma-derived sEVs from patients with vari-

predict their CAD stages through the models. The five methods used

ous degrees of CAD, including SP, NSTEMI, and STEMI CAD stages,

in this study are most common algorithms in ML for classification and

was developed. Plasma from patients without CAD was used as

prediction. Each method represents a typical type of algorithms in ML

healthy control (HC) group. We hypothesized that SERS data combin-

theory. All methods have predictive errors and statistical noises in the

ing with ML algorithms can accurately classify the sEVs from different

data, especially for large data set or data set with sampling limitations.

CAD stages and be used to predict potential risks in CAD patients.

Therefore, it is important to understand the performance difference

Firstly, we isolated and characterized sEVs from human plasma sam-

among these methods. Thus, we compared the diagnosis perfor-

ples with various degrees of CAD and collected their SERS signals

mances of the five models and demonstrated robust classifications
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and high accurate diagnosis in plasma-derived sEVs for early-stage

only based on a single pathology-related Raman spectroscopic peak is

CAD detection and CAD progression monitoring through the intro-

unlikely to be reliable and not suitable for diagnosis or classification of

duction of ML algorithms.

the disease status. The solution for better understanding of the data
is to apply ML methods to extract the diagnosis or classification information based on the entire spectral pattern.

2

RESULTS AND DISCUSSION

|

The first method we applied is discrimination analysis, which has
been widely used to classify and predict Raman spectra of various biological and biomedical samples.52 In this study, we chose QDA

2.1 | Plasma-derived sEV isolation and
characterizations

method since the classification (decision) boundaries of QDA can be
learned quadratically and flexibly compared to another often used

Plasma-derived sEVs were isolated from patient plasma using a stan-

method, linear discrimination analysis (LDA). The PCA plot colored by

dard procedure of ultracentrifugation as shown in Figure 2a. Ten sam-

QDA classification results is shown in Figure 3b, where each colored

ples from each group were used to evaluate plasma-derived sEV

dot represents a spectrum. It clearly shows the capabilities to separate

features. The AFM images showed that the vesicle morphology of the

different sEV subpopulations based on the SERS spectra; however,

most vesicles was flattened sphere-like with nanoscale sizes

overlaps are still observed. The overall classification accuracy per-

(Figure 2b), which was consistent with previous results.51 The vesicles

formed by cross-validation is 80.26% with a sensitivity of 96.28% and

typically consisted of membrane vesicles of 50–200 nm in diameter

a specificity of 74.37%. The sensitivity and specificity were calculated

according to the results of nanoparticle tracking analysis (NTA)

by counting HC group as negative and other three CAD stages

(Figure 2c,d). The sEVs in the HC group had relatively smaller average

together as positive. The heat map (Figure 3c) summarizes the predic-

size (Figure 2c). Additionally, the average size of vesicles in NSTEMI

tion possibility (range 0–1) by QDA for the HC group and three stages

group was the largest among the four groups with significant differ-

of CAD. Red color indicates the highest possibility (1), while blue color

ence (Figure 2c). The ranges of sEV concentration had wide distribu-

indicates the lowest possibility (0). By supervised QDA, the heat map

tion, and there was no significant difference among different groups

shows most predictions fall in the correct stages, but mispredictions

(Figure 2d). The markers of sEVs, the tetraspanin (CD63) and endoso-

and swings between two stages (yellow color, 0.5) are still observed.

mal pathway protein (Alix) were detected by Western blotting

To draw each receiver operating characteristic (ROC) curve, we

(Figure 2e). Both Alix and CD63 were expressed in sEVs and Calnexin

counted the representation stage as a positive response, and the

(negative marker) was not detected. These results confirmed that the

other three stages as the negative response for the calculation of Sen-

recovered vesicles were sEVs. Taken together, the size and content of

sitivityacc and Specificityacc. As an example, in the ROC curve of HC,

typical sEV protein markers indicated that sEVs were successfully iso-

the Sensitivityacc and Specificityacc are calculated as results of HC

lated from the human plasma samples from different stages of CAD

response against other three stages (SP, NSTEMI, and STEMI)

patients.

responses. Area under the curve (AUC) of ROC is the indicator of the
goodness of fit for the model, and a value of 1 indicates a perfect fit
and a value near 0.5 indicates that the model cannot discriminate

2.2 | Averaged Raman spectra for four stages of
CAD and QDA classification

among the stages. The AUC results by QDA for each stage range from
0.9366 to 0.9824, indicating the QDA method shows good fitting
results (Figure 3d). Furthermore, due to possible overfitting by the

To provide an overview of the Raman spectra of four CAD stages, all

cross-validation method, we also verified the QDA model by randomly

spectra after standard normal variate processing were simply aver-

splitting data into training and testing sets. In each round, 90% of data

aged and shown in Figure 3a. In the fingerprint region, spectra

(total 697 spectra) was used as a training set, and the remaining 10%

showed Raman peaks appeared to originate from lipids and proteins

of data (total 78 spectra) was used as a testing set. Only the training

which are the major contributors to sEV surface. For example, the

set was used to train the model, and the testing set was used for blind

vibrations contributed to symmetric ring breathing of tryptophan

prediction. A total of 50 rounds were performed to evaluate the loss

1

1

was observed

and accuracy change of the testing set. As shown in Figure 3e, we

corresponding to C O O vibration typical of phospholipids. Other

. A peak at 830 cm

found the averaged overall accuracy of QDA is 79.9% ± 3.9%, with a

peaks such as 856 cm1 (glycogen), 879 cm1 (C C stretch proline

minimum of 71.8% at round 10th and a maximum of 89.7% at round

ring), 1005 cm1 (phenylalanine), 1126 cm1 (C C vibrations in lipid),

12th, which is consistent with the cross-validation results.

appeared as a peak at 755 cm

1

1244 cm

1

(amide III), 1450 cm

(CH2 bending vibration of proteins/

lipids), and 1668 cm1 (amide I) were also observed.
When we closely look at each individual spectrum as shown in
Figure S1, the variations in spectra were significantly notable not only

2.3 | KNN, ANN, SVM, and XGB classifications and
predictions

across the four CAD stages but even within the same CAD stage. The
large variations are expected, because in spectroscopic measurement,

Besides QDA, we also implemented four other ML algorithms, includ-

the obtained data is semiquantitative, which means that analyzing

ing KNN, ANN, SVM, and XGB, to classify and predict CAD stages

5 of 11
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F I G U R E 2 Isolation and characterizations of sEV from human plasma. (a) Scheme of isolation procedure of sEVs from human plasma. (b) AFM
images of sEVs. (c, d) The size and concentration of sEVs by NTA test (n = 11, *p < 0.05). (e) Western blot analysis of biomarker proteins on sEVs

and compare the classification performances. Each method has its
53

own advantages and weaknesses.

QDA method allows nonlinear fit-

experimenting K = 1–30. For all methods, 90% of the full data set
was randomly split for training while the remaining 10% was used for

ting through data and the relationship between data and data inter-

testing. The process was also repeated for 50 rounds. Figure 3e shows

pretation could be established practically. KNN method depends on

the prediction accuracies for all the five classification methods used in

the nearby adjacent samples rather than the algorithm of discriminat-

this study. Results demonstrated that the SVM provided the highest

ing the class domain for classification, which may be more suitable for

and most robust prediction accuracy of 92.3% with a SD of 3.4%

dense overlapped data sets among multiple classes. ANN has more

among all five methods. XGB provides a low prediction accuracy of

tolerance to noise and missing data, and is good at handling high-

82.6%, but still better than previously used QDA method (79.9%).

dimensional data sets, but may have difficulty with data interpretation

Among the 50 round tests of ANN, although the averaged prediction

and algorithm structure understanding. SVM is also durable to noise

accuracy of ANN is 86.4%, there were 3 rounds of prediction accuracy

and has advantage in handling a small set of data and overfitting

below 70%, indicating ANN may lack stability due to a randomly cho-

issues. XGB is fast, but ideally requires nonoverlapped data set and an

sen training set. The averaged confusion matrix from the 50 round

inappropriate training set may lead to distorting the decisions.

tests is also shown in Table S1. For early CAD prediction (SP stage),

Same as QDA, the raw Raman data was preprocessed and per-

QDA, SVM, and ANN had the prediction accuracy of 88.7%, 85.9%,

formed by PCA initially. Fifteen PCs were chosen (Figure S2) as the

and 86.4%, respectively, much higher than the other two methods,

new input variables to the models. Then to compare the classification

which indicates these ML algorithms may work better for early CAD

accuracies from different methods, the model parameters also need to

detection. For the most severe stage (STEMI) prediction, all five algo-

be estimated properly since those parameters will significantly affect

rithms have similar performance. QDA, SVM, KNN, ANN, and XGB

the efficiency of the classification. Thus, obtaining the best possible

had the prediction accuracy of 84.7%, 88.5%, 86.8%, 89.1%, and

set of parameters is critical, both from the computing cost and com-

84.2%, respectively. For HC group prediction, SVM and KNN have

puting accuracy. Among these four classification methods, all of them

higher prediction accuracies of 95.7% and 91.6% over other three

have parameters that need to be determined. For ANN, the input is

algorithms. Through Table S2, we found SVM has the overall best per-

15 PCs, and the output is the 4-classification group. To avoid overfit-

formance over other four algorithms for prediction of all stages.

ting or underfitting, an ANN structure with two hidden layers was

Table 1 shows the averaged confusion matrix of sensitivity and speci-

chosen. The first hidden layer was set to have 10 neurons, and the

ficity from the 50 round tests. SVM method also had the highest sen-

second hidden layer was set to have 6 neurons. For XGB, 5000 deci-

sitivity (97.2%) and specificity (95.8%) among all the methods used in

sion trees were chosen. For SVM, the radial basis function kernel was

this study, since major classification errors occurred within the disease

chosen. In KNN, the best accuracy was obtained when K = 1 after

groups (SP to be misclassified as NSTEMI and NSTEMI to be

6 of 11
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F I G U R E 3 Raman spectra
and QDA analysis. (a) Averaged
Raman spectra for four stages of
CAD (HC, SP, NSTEMI, STEMI);
(b) The PCA plot colored by QDA
classification results of the total
775 Raman spectra from four
stages of CAD. (c) Heat map of
the prediction possibility (range
0–1) by QDA for four stages of
CAD. (d) ROC curves for each
representation stage and their
AUC values. (e) Prediction
accuracy of test sets performed in
QDA, SVM, KNN, ANN, and XGB
in 50 test rounds by randomly
splitting 90% of data into a
training set and 10% into a
test set

misclassified as SP). QDA shows the lowest specificity (74.8%) among

Figure 4c, Figure 4d,e shows the decision boundaries of SVM pro-

the five methods.

jected in the 2D PCA plot, PC1 vs PC2, and PC2 vs PC3, respectively.

2.4

2.5

|

SVM as the best ML method in this study

|

Challenges and future directions

The PCA plot colored by SVM classification results is shown in

sEVs serve as a mediator of intercellular communication between

Figure 4a, where each colored dot represents a spectrum. The heat

cells, and can be used as a noninvasive indicator of disease,54–56

map (Figure 4b) summarizes the prediction possibility (range 0–1) by

which is the strategy applied in this study to diagnose CAD status via

SVM for the HC group and three stages of CAD. Red color indicates

detecting and analyzing SERS signals from sEVs. However, although

the highest possibility (1) while the blue color indicates the lowest

as a promising clinical approach, the application of our study still faces

possibility (0). The heat map shows almost all predictions fall in the

several challenges. The first limitation is related to the major Raman

correct stages with a few swings between two stages (yellow color,

signals that are mostly derived from sEV surface molecules

0.5). The AUC results by SVM for each stage range from 0.9888 to

(e.g., membrane proteins, lipids).49,57,58 Thus, SERS signals may be

0.9967, indicating the SVM method shows excellent fitting results in

influenced by various membrane molecules.59 In order to identify
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TABLE 1

Averaged confusion matrix of sensitivity and specificity from the 50 round tests
Predicted class

Model

Sample comparison

QDA

SP + NSTEMI + STEMI vs HC

Positive

SVM

SP + NSTEMI + STEMI vs HC

KNN

SP + NSTEMI + STEMI vs HC

ANN

SP + NSTEMI + STEMI vs HC

XGB

SP + NSTEMI + STEMI vs HC

Negative

Positive

Negative

51.8

1.9

Negative

6.0

17.8

Positive

52.2

1.5

Negative

1.0

22.8

Positive

50.5

3.2

Negative

2.0

21.8

Positive

51.0

2.7

Negative

2.7

21.1

Positive

49.0

4.7

4.2

19.6

Sensitivity

Specificity

96.5%

74.8%

97.2%

95.8%

94.0%

91.6%

95.0%

88.7%

91.2%

82.4%

F I G U R E 4 SVM analysis. (a) A PCA plot colored by SVM classification results of the total 775 Raman spectra from four stages of CAD.
(b) Heat map of the prediction possibility (range 0–1) by SVM for four stages of CAD. (c) ROC curves for each representation stage and their AUC
values. (d) Decision boundaries of SVM projected in 2D PCA plot (PC1 vs PC2). (e) Decision boundaries of SVM projected in the 2D PCA plot
(PC2 vs PC3). (Black: HC; Red: SP; Green: STEMI; Blue: NSTEMI)

protein signatures existing in both surface and interior of sEV, we will

however, another issue may come out that the measurements

analyze sEV cargoes using other advanced technologies such as prote-

between different batches of patient samples obtained from national

omics.60 The second challenge is the patient number involved in this

wide may vary largely due to uncertain uniformity among different

study. One solution is to expand the obtained Raman library;

SERS methods and system errors coming from different Raman

8 of 11

HUANG ET AL.

instruments.44 Thus, it has to optimize the calibration condition before

pH = 7.4). The size and concentration of the final sEVs were exam-

each test to improve the precision of detection and analysis. The third

ined by NTA using a NanoSight (NS300) measurement. The exosome

challenge is that the isolated plasma sEVs may contain a variety of

morphology was evaluated as previously described by using atomic

sEVs derived from other organs and cells that are not related to the

force microscopy (AFM, Bruker).62

34,61

CAD.

Therefore, our future study will focus on expanding the

sample number and types of sEV samples to improve the robustness
and reliability of our approach, such as detection of sEVs from heart

4.2

|

Western blot

tissues with different CAD stages.
The markers (CD63 and Alix) of the isolated sEVs were correspondingly detected by Western blotting as reported previously.62,63 The

3

C O N CL U S I O N S

|

sEVs were lysed using the Mammalian Cell Lysis kit (Sigma–Aldrich)
and quantified using Pierce™ BCA Protein Assay Kit (Thermo Fisher

In summary, we successfully isolated sEVs from the human plasma

Scientific, 23227). The samples were preheated at 60 C for 15 min.

samples from four stages of CAD patients, that is, HC, SP, NSTEMI,

Proteins were electrophoresed in an SDS-polyacrylamide gel followed

and STEMI. SERS measurements in conjunction with five ML algo-

by transferring to PVDF membranes. The membranes were blocked

rithms were then applied for the classification and prediction of the

with 5% BSA in TBS-Tween 20 and were then probed with antibodies

sEV samples. The overall accuracy was 79.9%, 92.3%, 88.5%, 86.4%,

specific for CD63 (1:1000, ab216130, Abcam), Alix antibody (1:1000,

and 82.6% for QDA, SVM, KNN, ANN, and XGB, respectively. Among

Proteintech), and calnexin (1:1000, Proteintech, negative biomarker

these five approaches, SVM shows the best prediction results on both

for sEVs) overnight at 4 C. After three washes in TBS-tween 20, mem-

early CAD detection (86.4%) and overall prediction (92.3%). SVM also

branes were incubated with the secondary antibody (Thermo Scien-

possesses the highest sensitivity (97.69%) and specificity (95.7%).

tific) for 1 h and washed again. For visualization, blots were exposed

Thus, our study demonstrates a promising strategy for noninvasive,

to SuperSignal West Dura Extended Duration substrate and measured

safe, and high accurate diagnosis for early CAD detection.

by the FluorChem R system (ProteinSimple).

4

4.3

4.1

MATERIALS AND METHODS

|
|

sEV isolation and characterizations

|

SERS measurements

The sEV samples were immediately measured within 12 hours
after taking from 80 C. Gold-coated glass slides (Ti/Au

Deidentified human plasma samples were donated by the Nebraska

40 nm/100 nm, Deposition Research Lab Inc.) were used for better

Cardiovascular Biobank and Registry (IRB approved protocol

suppression of fluorescence background and surface plasmonic

133-14-EP). The human plasma was obtained from patients at the

enhancement for SERS. Five microliters of each sEV samples was

time of cardiac catheterization and immediately stored at 80 C for

dropped onto the gold slide and then measured immediately

further use. Samples were obtained from patients who presented with

before drying at room temperature. Raman spectra were recorded

chest pain and a positive stress test, and those who presented with a

using a commercial micro-Raman microscope (Renishaw InVia

NSTEMI or a STEMI. Patients who had nonobstructive CAD

Reflection) with 633-nm diode laser excitation. The laser power

(i.e., <50% lesions) at catheterization were defined as stable CAD

was set to 10 mW. The laser beam was focused on the 5 μl droplet

patients (SP). The bank ID, Gender, Age, Race of each patient is

by using a 50 microscope objective with a numerical aperture of

recorded in Table S2. sEVs were isolated from patient plasma with

0.75 (Leica n PLAN EPI 50/0.75). The laser spot is estimated to

three CAD stages, and the number of patients is 15 (SP stage),

be 1 μm in diameter. In the experiment, due to the sample avail-

15 (NSTEMI stage), and 17 (STEMI stage), respectively. The control

ability, the sample size was experimentally boosted by automated

samples (HC stage) were from 17 patients that had no signs of CAD.

measuring at different spots of the sEV droplet in 4  5 grid. Each

Among all sEV samples, 13 HC samples, 6 SP samples, 13 NSTEMI

Raman spectrum obtained for following analyzes was recorded

samples, and 8 STEMI samples were chosen for SERS test, and other

with an exposure time of 1 s and accumulated by 10 times. The

samples not used in SERS test were applied for NTA. The human

Raman data set is shown in Figure S3. Since the measurement was

plasma was first centrifuged at 300 g for 5 min, 1000  g for 20 min

automated and conducted on the sEV droplets by mapping pro-

and then at 10,000  g for 30 min sequentially. The supernatant was

gram, spectra with high background levels (high PBS peak and high

then filtered with a 0.22 μm filer, and ultracentrifuged (Sorval X + 80

background level) were obtained and then should be removed from

Ultracentrifuge, Thermo Fisher) at 100,000 g for 70 min. Subse-

the data set (Figure S4) to minizine the buffer influence on the fol-

quently, the sEV pellet was washed with PBS and ultracentrifuged at

lowing machine learning analysis. Thus, the total number of Raman

100,000  g for 70 min. The collected sEVs were reconstituted in

spectra obtained is 775, including 238 from 13 HC samples,

PBS buffer and then preserved at 80 C. For SERS analysis, parts of

120 from 6 SP samples, 257 from 13 NSTEMI samples, and

exosomes were resuspended in phosphate buffer (PB) (0.1 M,

160 from 8 STEMI samples.
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method.67 QDA is a classic type of binary classifier, which assumes

4.4 | Data preprocessing and classification
methods

normally distributed classes with unequal covariance. The two clas-

Data preprocessing of the raw Raman spectra included baseline cor-

ses respectively follow F0 ¼ Nðμ0 , Σ0 Þ and F 1 ¼ Nðμ1 , Σ1 Þ. For a fea

ture vector tj ¼ tj1 , tj2 , …, tjl , QDA predicts the likelihood ratio of

rection and normalization. Baseline correction was performed by Van-

the two classes,

couver Raman algorithm with five-point boxcar smoothing and a fiveorder polynomial fit. After baseline correction, the spectra were nor-



pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ1
T 

1
2π jΣ1 j exp  tj  μ1 Σ1 tj  μ1
2

 , j ¼ 1, 2, …, n
Lj ¼ pﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
T 

1
1
2π jΣ0 j exp  tj  μ0 Σ1 tj  μ0
2

malized using the standard normal variate technique, which can
remove multiplicative error and preserve each preprocessed spectrum
having same contribution to the following classification analysis.

4.5

Given a threshold of discrimination, T, if Lj < T, the tj is assigned

ML and classification methods

|

ð3Þ

class 0. Otherwise, it is assigned class 1. As shown in Figure S4, we
Classification analysis was adopted to identify the CAD stage based

compared the QDA classification accuracy for varying number of top

on SERS measurements. Raman spectra were processed to reduce

PCs, and 15 PCs were chosen (accounts for almost 91.2% of varia-

dimensionality, and then input to classifiers for CAD stage prediction.

tions in the data) for a good balance between high accuracy and small

Cross-validation (CV) was adopted for robust model training and vali-

number of features. Thus, these 15 PCs are used in all following ML

dation. The diagnostic capability of the classification models, charac-

models.

terized by sensitivity and specificity, was analyzed with Receiver
• Classification analysis. Four other supervised learning classification

Operating Characteristics (ROC).64

methods, SVM, KNN, ANN and XGB were also performed by R soft• Dimensionality reduction. Since the preprocessed spectra were of

ware on these 15 PCs which served as input variables. The 90% SERS

high dimensionality, classification analysis on these data directly

data set of sEVs were used to train the models. The remaining 10%

can be computationally expensive. Principal component analysis

spectral data were used to predict the CAD stages through the models.

(PCA),65 as a widely used method for dimensionality reduction and

• Analysis of diagnostic capability. To gain insights into the diagnostic

feature extraction, was adopted to extract crucial information, that

capability of the proposed method, we adopted receiver operating

is, features, from the spectra data. For a n  p data matrix,

characteristic (ROC) curves to analyze the classifiers' sensitivity and
specificity. The conventional ROC is a graphic representation of
the diagnostic capability for a binary classification model. It visualizes the model's true positive rate (TPR) against the false positive

X ¼ ½x1 , x2 , …, xp , xi ¼ ½x1i , x2i , …, xni T , i ¼ 1, …, p,

ð1Þ

rate (FPR) as the discriminant threshold varies.
TPR: rate of correctly predicting class 1 (TPR = sensitivity);

a row vector in X belongs to Rp . PCA uses singular value decomposi66

tion (SVD)

FPR: rate of falsely predicting class 1 (FPR = 1  specificity);

to extract l principal components (PCs) from X, with l < p.

Each PC consists of element


tkj ¼ xj1 , xj2 , …, xjp  wk , j ¼ 1, 2, …, n, k ¼ 1, 2, …, l,

TPR ¼

ð2Þ

TP
FP
; FPR ¼
TP þ FN
FP þ TN

ð4Þ

where wk is the weights extracted by SVD that map each row of with

For a complete ROC curve, the area under curve (AUC) represents

X to a PC. The extracted PCs are ranked based on the percentage of

the capability of accurately predicting the positive cases, which is the

data variance they explain. For example, the 1st PC explains the high-

larger the better. In our study, there are four classes. To enable the analy-

est percentage of data variance among all the PCs; the 2nd PC

sis with ROC curves, we counted the representation stage as positive

explains the 2nd largest percentage of data variance, so on and so

response and other three stages as the negative response for calculation

forth. These PCs are then the features to be used in subsequent clas-

of Sensitivityacc and Specificityacc in ROC curves. However, in other condi-

sification analysis. In this study, R software was used for PCA

tions, Sensitivity and Specificity for the five ML models were calculated by

implementation.

counting HC group as negative and other three CAD stages as positive.

• Feature selection. The PCA reduces the high dimensionality of the
Raman spectra (1008 independent variables from 648 cm1 to

4.6

|

Statistical analysis

1

1747 cm

) to a few PCs. To determine the optimal number of

PCs for following machine learning models, Quadratic Discriminant

The mean size of small extracellular vesicles is expressed as means

Analysis (QDA) was performed with leave-one-out cross-validation

± SD. The statistical differences among multiple groups were analyzed
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by ANOVA. The p values are shown in the figures as *p < 0.05, which
are considered to be statistically significant.
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